Related Experiment Videos
[Platelet function, hypertension and ischemic heart disease]
Insights
Treating hypertension reduces cerebrovascular disease but not coronary heart disease (CHD). High blood pressure increases platelet aggregation, which normalizes with treatment, suggesting a role in CHD development.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Vascular Biology
Context:
- Hypertension treatment impacts cardiovascular outcomes differently.
- Arteriosclerosis, the basis of coronary heart disease (CHD), involves platelet activation.
- Platelet activation can occur at damaged endothelium and via specific thrombocyte receptors.
Purpose:
- To investigate the relationship between mean arterial blood pressure (MAP), platelet aggregation, and coronary heart disease (CHD).
- To explore the potential role of platelet aggregation in the development of CHD.
Summary:
- Mild to moderate hypertension treatment reduces cerebrovascular disease but not CHD frequency.
- Patients with high MAP (>120 mmHg) exhibit increased platelet aggregation tendency, which normalizes upon blood pressure reduction.
- This hyper-aggregability appears linked to blood pressure, suggesting thrombocyte aggregation's significance in CHD development.
Impact:
- Findings support the theory that platelet aggregation plays a role in coronary heart disease.
- Understanding this link may inform future therapeutic strategies for CHD prevention.
- Highlights the differential impact of hypertension treatment on various cardiovascular diseases.
Abstract:
Treatment of mild to moderate hypertension does not result in any obvious reduction in the frequency of coronary heart disease (CDH) whereas the frequency of cerebrovascular disease is reduced. Platelet activation assumes a central role in the development of arteriosclerosis which is presumed to be the basis of coronary heart disease. Platelet activation may occur at sites of damaged endothelium (eg in the arteriosclerotic plaque) and by means of influencing specific thrombocyte receptors. The receptors may also be activated in vitro, which may be utilized experimentally. By means of stratification of material from the literature, it appears possible that patients with high mean arterial blood pressures (MAP) (over approximately 120 mmHg) have an increased tendency to platelet aggregation for ADP and adrenalin. This hyper-aggregability appears to be related to the blood pressure as it is normalized when MAP is reduced by treatment to values around 120 mmHg. If MAP is under 120 mmHg already, no further decrease in the tendency to platelet aggregation occurs. Some investigations suggest an effect on ischaemic heart disease on treatment of the most hypersensitive patients. The observations quoted in the present article are in agreement with the theory that thrombocyte aggregation may be of significance for development of CDH.